Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + GC in First-Line PD-L1+ Biliary Tract Cancer
NCT07733115Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in biliary tract cancer (BTC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate at 24 months. Started Jul 2026; status: recruiting.
02
Drugs
QL1706
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07733115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07733115.